Accessibility links
The State Of Care For Perinatal And Postpartum Depression : 1A Nearly one in seven people who give birth experience postpartum depression.

Right now, there's only one PPD medication, called brexanolone, currently approved by the FDA.

While it's known to be extremely effective, access is very limited.

But a revolution in treating perinatal and postpartum depression may be underway.

We talk with experts about the current landscape of treatment for perinatal and postpartum depression and what FDA approval of a new medication, zuranolone could mean.

Want to support 1A? Give to your local public radio station and subscribe to this podcast. Have questions? Find us on Twitter @1A.

1A

The State Of Care For Perinatal And Postpartum Depression

The State Of Care For Perinatal And Postpartum Depression

Listen · 32:11
  • Download
  • <iframe src="https://www.npr.org/player/embed/1032540765/1032543729" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
Enlarge this image

There's only one postpartum depression medication currently approved by the FDA. And while it's known to be extremely effective, access is limited. MARTIN BUREAU/AFP via Getty Images hide caption

toggle caption
MARTIN BUREAU/AFP via Getty Images

There's only one postpartum depression medication currently approved by the FDA. And while it's known to be extremely effective, access is limited.

MARTIN BUREAU/AFP via Getty Images

Nearly one in seven people who give birth experience postpartum depression.

Right now, there's only one PPD medication, called brexanolone, currently approved by the FDA. While it's known to be extremely effective, access is very limited.

But a revolution in treating perinatal and postpartum depression may be underway.

Earlier this summer, researchers published promising Phase 3 trial results of a new medication called zuranolone.

We talk with experts about the current landscape of treatment for perinatal and postpartum depression and what FDA approval of zuranolone could mean.

Sarah Verbiest, Dr. Kristina Deligiannidis, and Dr. Diana Ramos join us for the conversation.

Like what you hear? Find more of our programs online.